Skip to main content

Psychosexual Therapy

Psychosexual therapy is the set of psychological and behavioral interventions used to treat sexual dysfunction in men and women: sensate focus, cognitive behavioral therapy (CBT), mindfulness-based interventions (MBI), the PLISSIT counseling model, sex education and skills training, and couples or interpersonal therapy. The framework derives from Masters and Johnson and sits within the biopsychosocial model of sexual dysfunction.[1][2][3] The AUA 2018 ED guideline states that referral to a mental health professional should be considered in men treated for ED .[17] The AUA/SMSNA 2020 guideline (published 2022) gives the same recommendation for premature ejaculation (PE) .[6] ACOG Practice Bulletin 213 recommends sexual skills training, CBT, mindfulness-based therapy, and couples therapy as part of female sexual dysfunction treatment (Level B: limited or inconsistent evidence).[4] It advises considering specialist referral according to clinician expertise and patient needs.[4][5]

Foundations and core techniques​

Sexual dysfunction arises from an interplay of biological, psychological and sociocultural factors, and psychosexual therapy targets the psychological and relational contributors.[1][7]

TechniqueCore ideaKey uses
Sensate focus (Masters & Johnson)Structured exercises beginning with non-sexual physical touch progressing gradually to sexual touch; partners alternate touching and feedback. The exercises aim to reduce performance anxiety and shift focus from goal-oriented to pleasure-oriented intimacy.ED, FSIAD, dyspareunia, post-trauma reconnection using trauma-adapted touch with attention to readiness, dissociation and safety[8][9][11]
Cognitive behavioral therapy (CBT)Targets maladaptive thoughts, unreasonable expectations, cognitive distortions (e.g., self-monitoring during sex), and negative attitudes about sexuality. Helps build healthier sexual scripts and reduce anxiety.FSIAD, female orgasmic disorder, GPPPD, ED[8][15][13]
Mindfulness-based interventions (MBI)Present-moment, non-judgmental attention; reduces sexual distress and avoidance. Ranked first for sexual distress in the 2026 network meta-analysis of 45 studies and 4,726 women.FSIAD (especially with distress); breast-cancer-survivor sexual concerns (a 2024 active-comparator RCT found improvement with both online mindfulness sex therapy and supportive sex education, without a between-arm difference at six months)[10][19]
PLISSIT modelStepped-care framework: Permission, Limited Information, Specific Suggestions, Intensive Therapy. Ranked first for overall FSFI improvement in the same 2026 NMA.[10]Permission and limited information can begin in office; referral for more intensive therapy depends on clinician expertise and patient needs.[4]
Sex education and sexual skills trainingAnatomy, physiology, masturbation techniques, communication. Includes directed masturbation for orgasmic disorder.Female orgasmic disorder; men with limited sexual literacy; couples seeking partner-directed skill building[3][4]
Couples / interpersonal therapyRelationship dynamics, emotional intimacy, communication, partner-related contributors to dysfunction.Distress that is interpersonally driven; ED with partner concerns; FSIAD[7][8]

Indications in women​

Psychosexual therapy may address female sexual interest/arousal disorder, female orgasmic disorder, and genito-pelvic pain/penetration disorder; substance/medication-induced dysfunction also warrants review of the medication and substance history.[4][5][7]

PhenotypeEvidence
Female sexual interest / arousal disorder (FSIAD)CBT, MBI, couples therapy, and sexual skills training all supported. CBT and sex therapy are discussed for female sexual interest/arousal disorder.[5] In an older group-CBT study of 74 couples in which women had hypoactive sexual desire disorder, 74% of the women were considered improved or cured after treatment and 64% at one year.[8][20]
Female orgasmic disorderSexual skills training (including directed masturbation) is the primary treatment.[4] Education about clitoral stimulation, body awareness, addressing guilt / shame. Women with female orgasmic disorder related to sexual assault may benefit from a trauma-informed psychotherapeutic approach.[4][11]
Genito-pelvic pain / penetration disorder (vaginismus, dyspareunia)Pelvic floor PT is recommended for GPPPD (ACOG Level C), particularly when pelvic-floor dysfunction contributes; GSM-related dyspareunia also needs cause-directed treatment.[4][21] Psychosexual therapy using systematic desensitization, graded vaginal dilators, relaxation and CBT is commonly combined with it.[5] The 2012 Cochrane review included five studies, four with usable data on 282 participants; it detected no clinical or statistical difference between systematic desensitization and control interventions, though a clinically relevant effect could not be ruled out.[9] A 2026 synthesis of 15 RCTs (950 participants) found improved penetration outcomes across varied interventions (SMD 0.61, 95% CI 0.38–0.84), while pooled independent pain outcomes were not significant and sexual-function results were highly heterogeneous (I² 93%).[18]

Across 20 RCTs of psychological interventions for sexual dysfunction in men and women, pooled post-treatment effects versus wait-list controls were d = 0.58 for symptom severity and d = 0.47 for sexual satisfaction.[12] Evidence was strongest for women with hypoactive sexual desire disorder and orgasmic disorder.[12]

Indications in men​

PhenotypeEvidence
Delayed ejaculationAUA/SMSNA recommends considering referral for lifelong or acquired delayed ejaculation to a mental health professional with sexual-health expertise . Psychobehavioral strategies may address barriers to arousal, while medication effects and comorbid ED require assessment.[6]
Erectile dysfunction (psychogenic component or adjunct)Cochrane 2007 (Melnik): in five pooled trials (N = 100), group psychotherapy reduced persistence of ED compared with wait-list at post-treatment (RR 0.40; 95% CI 0.17–0.98). At 6 months, the estimate was RR 0.43 (95% CI 0.26–0.72) in 37 men. Group therapy plus sildenafil reduced persistence of ED more than sildenafil alone (RR 0.46; 2 trials, N = 71). One trial of 20 men found group therapy alone superior to sildenafil on the IIEF.[13] AUA 2018: referral to a mental health professional should be considered .[17]
Premature ejaculation (PE)AUA/SMSNA 2020 (published 2022): clinicians should consider referring men with PE to a mental health professional with sexual-health expertise . Studies of behavioral techniques (stop-start, squeeze) suggest benefit, but trial quality and methods vary.[6][14]
Combined approachA systematic review of 20 controlled trials of male sexual dysfunction interventions (Berner & Günzler 2012) found that psychosocial interventions improved sexual functioning, and 12 of the 20 used a Masters-and-Johnson or CBT concept. Methodological quality was generally low. Long-term studies suggest stable improvement in sexual satisfaction, while symptom reduction may be less durable, which supports adding relapse-prevention strategies.[14][3]

Combined therapy — psychosexual + pharmacologic​

Combination therapy is supported most directly in ED:[7][13]

  • ED. The 2026 EAU guideline strongly recommends CBT, including the partner when indicated, combined with medical treatment. In older small trials, group therapy plus sildenafil reduced persistence of ED more than sildenafil alone, with lower dropout.[25][13]
  • PE. AUA/SMSNA advises counseling that combined behavioral and pharmacological approaches may be more effective than either alone .[6]
  • Female sexual dysfunction. Match medication to the condition: flibanserin for acquired generalized HSDD in women younger than 65, after alcohol counseling and exclusion of moderate or strong CYP3A4 inhibitors or hepatic impairment; bremelanotide for premenopausal acquired generalized HSDD, contraindicated with uncontrolled hypertension or known cardiovascular disease; vaginal estrogen or prasterone for postmenopausal GSM-related dyspareunia; and off-label transdermal testosterone for postmenopausal HSDD with monitoring and counseling about unknown long-term safety.[22][23][4] Psychosexual care may address coexisting distress or relationship factors.[5][1][4][22][23]
  • Mixed organic and psychogenic etiology is common in older men and in women with dyspareunia and calls for both psychotherapy and medical treatment.[3]

Comparative effectiveness (women) — Qiangzhao 2026 network meta-analysis​

InterventionBest forRanking
PLISSIT modelImproving overall sexual function (FSFI)1st for function
CBTFunction and distress reduction2nd for function; 3rd for distress
General sexual counselingImproving sexual function3rd for function
Mindfulness-based interventionsReducing sexual distress (FSDS)4th for function; 1st for distress
Sex educationBroad improvement5th for function; 2nd for distress

These are SUCRA rankings from a network meta-analysis of 45 studies (4,726 women), chiefly reflecting comparisons with usual care or controls.[10] Head-to-head superiority is unestablished and trial counts for some approaches were limited.[10]

Practical considerations​

  • Format. Formats are individual, couple, group or online (telehealth access has expanded since COVID-19). The number of sessions varies, and both partners are included when possible.[6][8]
  • Referral. ACOG advises that consultation with or referral to mental health specialists with expertise in female sexual dysfunction, such as sex therapists, psychologists, psychiatrists, or marriage or relationship counselors, be considered according to the clinician's own expertise and the patient's needs.[4]
  • Format choice. The format is matched to the dominant contributor: intrapsychic (individual), interpersonal (couple) or psychoeducational (group).
  • Limitations. The evidence is limited by small samples, heterogeneous populations, variable outcome measures and generally low methodological quality.[14][15][8][1]
  • Durability. Long-term studies indicate that improvements in sexual satisfaction tend to be more stable than reductions in specific sexual symptoms, so relapse-prevention strategies are incorporated.[3]

Clinical scenarios for psychosexual referral​

  • Primary psychogenic ED with negligible organic component, or ED dominated by performance anxiety in younger men.[2][13]
  • PE with significant interpersonal distress, including when medication is declined or contraindicated. The 2026 EAU guideline notes weak and inconsistent evidence for psychosexual therapy alone and unknown long-term outcomes; for acquired PE, it weakly recommends behavioral, cognitive, or couple therapy combined with pharmacotherapy when appropriate.[6][14][24]
  • FSIAD with distress. MBI is an option, but its first-place rank for reducing Female Sexual Distress Scale scores in the 2026 network meta-analysis pooled mixed female sexual-function studies.[10][4]
  • Female orgasmic disorder (sexual skills training is the canonical treatment).[4]
  • Vaginismus / GPPPD as integral adjunct to PFPT and graded dilators.[5][9]
  • SPS / PDD. Body-image and dysmorphic distress in men with objectively normal anatomy. Before invasive cosmetic penile augmentation by injection or surgery, the SMSNA position statement calls for ruling out penile dysmorphic disorder and for structured psychological assessment and counseling when objective deformity is absent.[16]
  • Post-trauma sexual recovery. Trauma-informed sex therapy.[11]
  • Mixed organic and psychogenic dysfunction. Combine with pharmacologic or mechanical treatment.[3][13]

See Also​

References​

1. Davis SR. Sexual dysfunction in women. N Engl J Med. 2024;391(8):736–745. doi:10.1056/NEJMcp2313307

2. Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381(9861):153–165. doi:10.1016/S0140-6736(12)60520-0

3. Kockott G. Psychotherapy for sexual dysfunctions and desire disorders. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007;50(1):11–18. doi:10.1007/s00103-007-0112-2

4. Committee on Practice Bulletins—Gynecology, American College of Obstetricians and Gynecologists. Female sexual dysfunction: ACOG Practice Bulletin No. 213. Obstet Gynecol. 2019;134(1):e1–e18. doi:10.1097/AOG.0000000000003324

5. Dalrymple SN, Hoeg L, Thacker H. Female sexual dysfunction: common questions and answers. Am Fam Physician. 2025;111(5):433–442. PMID 40378324

6. Shindel AW, Althof SE, Carrier S, et al. Disorders of ejaculation: an AUA / SMSNA guideline. J Urol. 2022;207(3):504–512. doi:10.1097/JU.0000000000002392

7. Brotto L, Atallah S, Johnson-Agbakwu C, et al. Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med. 2016;13(4):538–571. doi:10.1016/j.jsxm.2016.01.019

8. Basson R. Sexual desire and arousal disorders in women. N Engl J Med. 2006;354(14):1497–1506. doi:10.1056/NEJMcp050154

9. Melnik T, Hawton K, McGuire H. Interventions for vaginismus. Cochrane Database Syst Rev. 2012;12:CD001760. doi:10.1002/14651858.CD001760.pub2

10. Qiangzhao L, Qiong L, Bohong G, et al. Psychological therapies for female sexual function: a systematic review and network meta-analysis. J Sex Med. 2026;23(3):qdag040. doi:10.1093/jsxmed/qdag040

11. Almås E, Benestad EEP. Treatment of traumatised sexuality. Front Psychol. 2021;12:610619. doi:10.3389/fpsyg.2021.610619

12. Frühauf S, Gerger H, Schmidt HM, Munder T, Barth J. Efficacy of psychological interventions for sexual dysfunction: a systematic review and meta-analysis. Arch Sex Behav. 2013;42(6):915–933. doi:10.1007/s10508-012-0062-0

13. Melnik T, Soares BG, Nasselo AG. Psychosocial interventions for erectile dysfunction. Cochrane Database Syst Rev. 2007;(3):CD004825. doi:10.1002/14651858.CD004825.pub2

14. Berner M, Günzler C. Efficacy of psychosocial interventions in men and women with sexual dysfunctions — Part 1: male sexual dysfunction. J Sex Med. 2012;9(12):3089–3107. doi:10.1111/j.1743-6109.2012.02970.x

15. Günzler C, Berner MM. Efficacy of psychosocial interventions in men and women with sexual dysfunctions — Part 2: female sexual dysfunction. J Sex Med. 2012;9(12):3108–3125. doi:10.1111/j.1743-6109.2012.02965.x

16. Trost L, Khera M, Köhler T, et al. Cosmetic penile enhancement procedures: an SMSNA position statement. J Sex Med. 2024;21(6):573–578. doi:10.1093/jsxmed/qdae045

17. Burnett AL, Nehra A, Breau RH, et al. "Erectile Dysfunction: AUA Guideline." J Urol. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004

18. Karaahmet AY, Bilgiç FŞ. "The Effectiveness of Therapeutic Interventions on Sexual Function in Women with Vaginismus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Int J Sex Health. 2026;38(3):947-968. doi:10.1080/19317611.2025.2612232

19. Brotto LA, Walker L, Sears C, Woo S, Millman R, Zdaniuk B. "A randomized comparison of online mindfulness-based group sex therapy vs supportive group sex education to address sexual dysfunction in breast cancer survivors." J Sex Med. 2024;21(5):452-463. doi:10.1093/jsxmed/qdae022

20. Trudel G, Marchand A, Ravart M, et al. "The effect of a cognitive-behavioral group treatment program on hypoactive sexual desire in women." Sex Relatsh Ther. 2001;16(2):145–164. doi:10.1080/14681990120040078

21. Torosis M, Carey E, Christensen K, et al. "A Treatment Algorithm for High-Tone Pelvic Floor Dysfunction." Obstet Gynecol. 2024;143(4):595–602. doi:10.1097/AOG.0000000000005536

22. U.S. Food and Drug Administration. "ADDYI (flibanserin) tablets: Prescribing information." FDA Label. Revised December 2025. Full text

23. Cosette Pharmaceuticals. "VYLEESI (bremelanotide injection): Prescribing information." DailyMed. Revised March 2024; updated November 13, 2025. Full text

24. European Association of Urology. "EAU Guidelines on Sexual and Reproductive Health: Disorders of Ejaculation." EAU Guidelines. 2026. Full text

25. European Association of Urology. "EAU Guidelines on Sexual and Reproductive Health: Management of Erectile Dysfunction." EAU Guidelines. 2026. Full text